NIKKEI 225
38,570.76 +88.65 (+0.23%) HANG SENG
18,430.39 +514.84 (+2.87%) CRUDE OIL
81.47 -0.10 (-0.12%) GOLD FUTURES
2,342.70 -4.20 (-0.18%) DOW
38,834.86 +56.76 (+0.15%) Bitcoin GBP
51,018.70 +368.56 (+0.73%)
uniQure N.V. (UQ1.F)
| Previous close | 4.1740 |
| Open | 4.0600 |
| Bid | 4.0600 x 70000 |
| Ask | 4.4600 x 60000 |
| Day's range | 4.0600 - 4.0600 |
| 52-week range | 3.9030 - 17.5400 |
| Volume | |
| Avg. volume | 3 |
| Market cap | 200.935M |
| Beta (5Y monthly) | 1.08 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease
~ Designation based on 24-month interim Phase I/II clinical data for AMT-130 announced in December 2023 ~ ~ AMT-130 is the first therapeutic candidate to receive RMAT Designation for Huntington’s disease ~ ~ Receiving RMAT designation enables increased collaboration with the FDA on regulatory approval planning, in addition to the opportunity for expedited product development ~ LEXINGTON, Mass. and AMSTERDAM, June 03, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy co
- GlobeNewswire
uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
~ On track to initiate FDA interaction regarding AMT-130 in second quarter of 2024 and provide a clinical update from the Phase I/II trials in mid-2024 ~ ~ Clinical trial initiation for Fabry disease on track to begin in second quarter of 2024, followed by refractory mesial temporal lobe epilepsy and SOD1-ALS in third quarter of 2024 ~ ~ Comprehensive review of operations and options to reduce expenses underway and expected to be completed in mid-2024 ~ LEXINGTON, Mass. and AMSTERDAM, May 07, 20
- GlobeNewswire
uniQure Announces 2023 Financial Results and Highlights Recent Company Progress
~ Presented promising clinical update from U.S. and European Phase I/II trials of AMT-130 in Huntington’s disease; Up to three years of follow-up data to be presented in mid-2024; Regulatory interactions and clarity on potential strategies for clinical development expected in 2024 ~ ~ Announced FDA clearance of two Investigational New Drug (IND) applications; Initiation of Phase I/II clinical trials in mesial temporal lobe epilepsy (mTLE) and Fabry disease, in addition to SOD1-ALS, are expected
